NCT02713529View on ClinicalTrials.gov

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

January 2, 2019

Study Completion Date

May 17, 2019

Conditions
Pancreatic CancerColorectal CancerNon-Small Cell Lung Cancer
Interventions
BIOLOGICAL

AMG820 and pembrolizumab

Treatment with AMG820 and pembrolizumab

Trial Locations (15)

2050

Research Site, Camperdown

2610

Research Site, Wilrijk

3050

Research Site, Parkville

10021

Research Site, New York

19111

Research Site, Philadelphia

28040

Research Site, Madrid

28050

Research Site, Madrid

29605

Research Site, Greenville

30332

Research Site, Atlanta

49546

Research Site, Grand Rapids

69120

Research Site, Heidelberg

78229

South Texas Accelerated Research Therapeutics, San Antonio

02114

Research Site, Boston

02215

Research Site, Boston

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

AmMax Bio, Inc.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AmMax Bio, Inc.

INDUSTRY

NCT02713529 - Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | Biotech Hunter | Biotech Hunter